» Articles » PMID: 35656811

Low Dose Betahistine in Combination With Selegiline Increases Cochlear Blood Flow in Guinea Pigs

Overview
Date 2022 Jun 3
PMID 35656811
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Betahistine is frequently used in the pharmacotherapy for Menière's Disease (MD). Little is known about its mode of action and prescribed dosages vary. While betahistine had an increasing effect on cochlear microcirculation in earlier studies, low dose betahistine of 0.01 mg/kg bw or less was not able to effect this. Selegiline inhibits monoaminooxidase B and therefore potentially the breakdown of betahistine. The goal of this study was to examine whether the addition of selegiline to low dose betahistine leads to increased cochlear blood flow.

Methods: Twelve Dunkin-Hartley guinea pigs were anesthetized, the cochlea was exposed and a window opened to the stria vascularis. Blood plasma was visualized by injecting fluoresceinisothiocyanate-dextrane and vessel diameter and erythrocyte velocity were evaluated over 20 minutes. One group received low dose betahistine (0.01 mg/kg bw) and selegiline (1 mg/kg bw) i.v. while the other group received only selegiline (1 mg/kg bw) and saline (0.9% NaCl) as placebo i.v.

Results: Cochlear microcirculation increased significantly ( < .001) in guinea pigs treated with low dose betahistine combined with selegiline by up to 58.3 ± 38.7% above baseline over a period of up to 11 minutes. In one guinea pig, the increase was 104.6%. Treatment with Selegiline alone did not affect microcirculation significantly.

Conclusions: Low dose betahistine increased cochlear microcirculation significantly when combined with selegiline. This should be investigated in further studies regarding dose-effect relation in comparison to betahistine alone. Side effects, in particular regarding circulation, should be considered carefully in view of the clinical applicability of a combination therapy in patients with MD.

Citing Articles

Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans-a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST).

Strupp M, Churchill G, Naumann I, Mansmann U, Al Tawil A, Golentsova A Front Neurol. 2023; 14:1271640.

PMID: 37920833 PMC: 10619746. DOI: 10.3389/fneur.2023.1271640.

References
1.
Gluth M . On the Relationship Between Menière's Disease and Endolymphatic Hydrops. Otol Neurotol. 2019; 41(2):242-249. DOI: 10.1097/MAO.0000000000002502. View

2.
Matos M, Rodriguez-Enriquez F, Borges F, Santana L, Uriarte E, Estrada M . 3-Amidocoumarins as Potential Multifunctional Agents against Neurodegenerative Diseases. ChemMedChem. 2015; 10(12):2071-9. DOI: 10.1002/cmdc.201500408. View

3.
Arpornchayanon W, Canis M, Ihler F, Settevendemie C, Strieth S . TNF-α inhibition using etanercept prevents noise-induced hearing loss by improvement of cochlear blood flow in vivo. Int J Audiol. 2013; 52(8):545-52. DOI: 10.3109/14992027.2013.790564. View

4.
Canis M, Arpornchayanon W, Messmer C, Suckfuell M, Olzowy B, Strieth S . An animal model for the analysis of cochlear blood flow [corrected] disturbance and hearing threshold in vivo. Eur Arch Otorhinolaryngol. 2009; 267(2):197-203. DOI: 10.1007/s00405-009-1036-2. View

5.
Baker M, WAYLAND H . On-line volume flow rate and velocity profile measurement for blood in microvessels. Microvasc Res. 1974; 7(1):131-43. DOI: 10.1016/0026-2862(74)90043-0. View